Compounded vs branded GLP-1: regulatory status, sourcing, and what the evidence actually says

“Compounded semaglutide” sounds like a generic version of Wegovy or Ozempic at a fraction of the price. It is not. The branded product and the compounded product can share a molecule name while differing on almost everything that matters for safety: who reviewed the formulation, who verified the dose, and whether anyone has tested that specific preparation in people. The regulatory facts here are precise, and the evidence picture is genuinely thin — both deserve to be stated plainly.

What “compounded” actually means

Compounding is the practice of a licensed pharmacy preparing a customized medication for an individual patient. In the United States it is regulated chiefly under two sections of federal law: traditional pharmacies operate under section 503A, and larger “outsourcing facilities” under section 503B. Critically, compounded drugs are not FDA-approved. The FDA does not review a compounded preparation for safety, efficacy, or manufacturing quality before it reaches a patient — that pre-market review is exactly what distinguishes an approved product like branded semaglutide or tirzepatide.

Why so much GLP-1 got compounded

Federal law generally bars compounding a copy of a commercially available, approved drug. A major exception applies when that drug is on the FDA's official shortage list. Semaglutide and tirzepatide spent extended periods on that list as demand outran supply, which opened a legal window for pharmacies to compound versions of them. As the FDA subsequently declared those shortages resolved, that window began to close — and the agency set timelines after which compounding the shortage-based copies would no longer be permitted. The practical takeaway: the legal status of a compounded GLP-1 has been a moving target tied directly to shortage declarations, not a stable generic-drug pathway.

What the evidence does — and doesn't — say

Here is the load-bearing distinction. The efficacy numbers people associate with these drugs come from trials of the branded, approved products: semaglutide 2.4 mg produced about 14.9% mean weight loss in STEP 1,^[1] and tirzepatide produced up to roughly 20.9% in SURMOUNT-1.^[2] Those results were generated with specific, FDA-reviewed formulations. They do not automatically transfer to a compounded preparation that may use a different salt form, a different concentration, or a different excipient base. A 2026 review put it directly: compounded semaglutide and tirzepatide products use unique formulations, and their efficacy and safety are largely unknown.^[3] No one has run STEP 1 on the compounded version sitting in a given vial.

The concrete safety signal: dosing errors

The most documented real-world harm has not been a chemistry scandal but a dosing one. Compounded GLP-1 often ships as a multi-dose vial drawn up with a syringe, rather than the pre-set pen that branded products use. A poison-control case series reported administration errors with compounded semaglutide — patients drawing up the wrong volume and receiving many times the intended dose, with predictable nausea, vomiting, and worse.^[4] The branded pen is engineered specifically to make that mistake hard to commit. Strip out that engineering and you transfer the risk to the patient and a handwritten label.

The honest bottom line

Compounded GLP-1 is not a counterfeit and not inherently dangerous — reputable pharmacies exist and the molecule may be identical on paper. But three facts should anchor any decision: it is not FDA-approved or pre-market reviewed; its legal availability has hinged on shortage declarations that are being unwound; and the trial evidence everyone cites belongs to the branded product, not to the compounded formulation in front of you. Lower price is real. So is the evidence gap. Anyone choosing the compounded route should do it with eyes open about exactly which of those they are trading.